noretreat, it's a small price to pay ($8m) for the right of first refusal.

1. Length of the deal - Apr 15th (why not Apr 1, hahaha), 2019 - might be around the time that BoM is complete.
2. Deal is only 60 days if either of the parties want out after that time. 
3.            The FA should be done in 60 days.
4.            Also, new financing needed in 60 to 120 days I would guess.
5. It does show that this insider (Hepa) has some hope and is buying cheap insurance.
6. Raises the issue of what if FA fails. Hepa may back out of this deal and yet buy out RVX if the share price collapses?
7. It does send a signal to BP that they are not just dealing with RVX. I would think this would be a huge loss to AZ, Pfizer and others.
8. China at a population of 1.4 billion and the USA at 323 million both are stricken by growth in obesity resulting in CVD, DM, CKD and many other diseases represent huge markets financially. A win for Hepa in both countries will make them a company that will leep frog from halperin to being a major player in many diseases and, at least with apabetalone, a big player in epigenetics.
9. Deal includes "products containing RVX-208 (apabetalone)". I wonder how many products that will be?
10. RVX still controls the patents and IP.

Will retail shareholders benefit?

GLTA

Toinv